Ken Griffin’s Janux Therapeutics JANX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.9M Sell
352,177
-751,967
-68% -$10.3M ﹤0.01% 4370
2025
Q4
$15.2M Buy
1,104,144
+301,360
+38% +$7.09M ﹤0.01% 2686
2025
Q3
$19.6M Sell
802,784
-428,342
-35% -$10.4M ﹤0.01% 2369
2025
Q2
$28.4M Buy
1,231,126
+524,462
+74% +$13.8M ﹤0.01% 1743
2025
Q1
$19.1M Sell
706,664
-654,214
-48% -$24.7M ﹤0.01% 2093
2024
Q4
$72.9M Buy
1,360,878
+351,110
+35% +$18.6M 0.01% 964
2024
Q3
$45.9M Sell
1,009,768
-547,348
-35% -$23.8M 0.01% 1296
2024
Q2
$65.2M Sell
1,557,116
-793,122
-34% -$37.2M 0.01% 947
2024
Q1
$88.5M Sell
2,350,238
-769,967
-25% -$16.8M 0.02% 784
2023
Q4
$33.5M Sell
3,120,205
-311,004
-9% -$2.69M 0.01% 1516
2023
Q3
$34.6M Buy
3,431,209
+1,315,635
+62% +$15.2M 0.01% 1387
2023
Q2
$25.1M Buy
2,115,574
+262,548
+14% +$3.51M 0.01% 1656
2023
Q1
$22.4M Sell
1,853,026
-1,785
-0.1% -$29.7K ﹤0.01% 1808
2022
Q4
$24.4M Buy
1,854,811
+1,595
+0.1% +$23.3K 0.01% 1751
2022
Q3
$25.1M Sell
1,853,216
-216
-0% -$2.89K 0.01% 1652
2022
Q2
$22.6M Hold
1,853,432
0.01% 1720
2022
Q1
$26.6M Hold
1,853,432
0.01% 1679
2021
Q4
$36.6M Sell
1,853,432
-5,814
-0.3% -$122K 0.01% 1434
2021
Q3
$39.6M Sell
1,859,246
-27,466
-1% -$790K 0.01% 1311
2021
Q2
$46.2M Buy
+1,886,712
New +$42M 0.01% 1192

Other funds holding JANX

Ken Griffin's JANX Position: Q1 2026 in Review

Ken Griffin reduced its Janux Therapeutics (JANX) stake by 68% in Q1 2026, selling an estimated $10.3M and leaving 352,177 shares worth $4.9M. The position accounts for ﹤0.01% of the portfolio, ranked #4370.

Ken Griffin first reported a position in JANX in Q2 2021 and has held it in 20 quarters since. The position peaked at $88.5M in Q1 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Ken Griffin held 352,177 shares of Janux Therapeutics worth $4.9M as of Q1 2026.
  • Ken Griffin sold 751,967 Janux Therapeutics shares in Q1 2026, an estimated $10.3M.
  • Janux Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #4370 holding.
  • Ken Griffin first reported a position in Janux Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Ken Griffin's Janux Therapeutics position peaked at $88.5M in Q1 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.